Nationwide trends in antidiabetic drugs (type-2) utilization, Ukraine, 2014–2016

Abstract

Introduction: Type 2 diabetes is the most common form of diabetes. According to the guidelines of International Diabetes Federation, patients need to be given appropriate medical treatment, the purpose of which is to achieve the compensation of the disease and the treatment of its complications. The aim of this study was to analyze the consumption and expenditure per day of oral antidiabetic medicines in Ukraine during 2014–2016. Materials and Methods: Study of drug consumption was conducted using anatomical therapeutic chemical/defined daily dose (ATC/DDD) methodology by calculating such figures as utilization in DDD, DDDs per 1000 inhabitants per day, and expenditure per DDD. Results and Discussion: The consumption rates of DDDs/1000 PD of monoantidiabetic drugs fluctuated from 11.57 to 15.45 DDDs/1000 PD, and for combined antidiabetic drugs, it was changed from 1.02 to 1.11 DDDs/1000 PD during 2014–2016. The structure of consumption in Ukraine 2015–2016 shows increasing in consumption of biguanides (51.21%), sulfonylureas (74.57%), repaglinide (91.67%), liraglutide (40%), pioglitazone (33.3%), and dapagliflozin (35%). The analysis of expenditure per DDD shows that the most affordable unit of DDD was agents that contain pioglitazone, metformin, sulfonylureas group, and combined drugs. Conclusion: Nationwide trends in antidiabetic agents’ utilization were analyzed in Ukraine during 2014–2016. It has been established a slight decreasing of A10B group agents’ consumption in the period of 2014–2015. In 2016, there was a tendency to increase the value of DDDs/1000 PD.